10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring 

Second Major Regional Licensing and Strategic Investment Agreement in 2026; Further Validates 10XB-101 Global Commercial Market Potential

 Leios Therapeutics (“Leios” or “The Company”), a clinical-stage biotechnology company focused on innovative aesthetic therapies,announced an exclusive licensing agreement for 10XB-101, a proprietary injectable therapy containing polidocanol, and a related strategic equity investment, by subsidiaries of China Medical System Holdings Limited (“CMS”) (Hong Kong Stock Code: 867, Singapore Stock Code: 8A8), an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals.

“The agreement with CMS represents an important strategic milestone for Leios Therapeutics, validating our market-by-market commercialization model and the scientific promise of 10XB-101,” said Ted White, Chief Executive Officer of Leios Therapeutics. “CMS is an established pharmaceutical company with growing international activities, and this partnership will enable us to reach one of the world’s largest markets. Their decision to license 10XB-101 following a rigorous diligence process underscores the strength of our clinical data and commercial potential. Together with CMS, we look forward to accelerating development and expanding access to 10XB-101 in China. We are progressing our trial initiation activities and expect to commence the trial in early 2027.”

This is the second major licensing and investment agreement signed in 2026 for the Company, and follows its partnership with BNC Korea. Together, the agreements establish Leios's presence in two of the most important markets for cosmetic procedures and skin care innovation outside the United States. South Korea serves as the global trendsetter in aesthetics, while China represents the volume powerhouse.

Under the licensing agreement, CMS receives exclusive rights to develop, manufacture and commercialize 10XB-101 in mainland China (including Hong Kong and Macau). Leios will receive an upfront payment, regulatory and commercial milestone payments, and royalties on future net sales, and will support the advancement of its 10XB-101 clinical development program. In a separate transaction, CMS agreed to make a strategic equity investment in Leios.

In its Phase 2b study in submental fat reduction, 10XB-101 demonstrated compelling efficacy, with 64% and 70% of completers in the higher dose groups (3.0% and 4.5%) achieving a grade 2 or greater improvement on both the clinician-reported and patient-reported submental fat scales (CSFS and PSFS), compared to 0% on placebo. Importantly, 10XB-101 demonstrated a clean safety profile across the study¹. Trial initiation activities are well underway, and the Company expects to commence the trial in early 2027.

Vault Advisors acted as the exclusive financial advisor to Leios Therapeutics for this transaction.